

HIV-1 Therapeutic Inhibits Viral Entry

Summary

The National Cancer Institute seeks parties to co-develop soluble forms of CD4 as potent HIV-1 therapeutics.

NIH Reference Number

E-033-2013

Product Type

- Therapeutics

Keywords

- HIV
- entry inhibitor
- CD4
- soluble expression
- MHCII

Collaboration Opportunity

This invention is available for licensing.

Contact

- Rose Freel
NCI TTC

rose.freel@nih.gov (link sends e-mail)

Description of Technology

Soluble forms (sCD4) of human CD4, the HIV-1 primary receptor, are potent HIV-1 entry inhibitors. Both four-domain (D1-4) and two-domain (D1D2) sCD4 and their fusion proteins have been tested as candidate therapeutics in animal models and in human clinical trials and were well tolerated by patients with no significant clinical or immunologic toxicities and exhibited significant inhibitory activities. However, their activities were transient and the virus rapidly rebound. Additionally, sCD4 is known to interact with the class II major histocompatibility complex (MHCII) and, at low concentrations, it could enhance the HIV-1 infectivity. Researchers at the National Cancer Institute's Nanobiology Program generated a novel polypeptide comprising a single human CD4 domain (mD1.22) that is highly soluble, stable and shows significantly increased neutralizing activity without measurable

interaction with MHCII.

Potential Commercial Applications

- As a prophylactic or an HIV therapeutic when conjugated with cytotoxic molecules
- Reagents for the rapid detection of HIV

Competitive Advantages

- Enhanced safety profile due to a lack of measurable interaction with MHCII
- Can be solubly expressed in *E. coli* with high yields leading to decreased production costs

Inventor(s)

Dimiter Dimitrov (NCI)

Development Stage

- Discovery (Lead Identification)

Publications

W. Chen et al. [[PMID 21715496](#)]

W. Chen et al. [[PMID 20709110](#)]

Patent Status

- **U.S. Patent Filed:** U.S. Patent Application Number 15/784,988, Filed 16 Oct 2017

Related Technologies

- [E-103-2010 - Single domain CD4, HIV-1 Antibodies, and Fusion Proteins for treatment of HIV](#)

Therapeutic Area

- Cancer/Neoplasm
- Infectious Diseases

Updated

Wednesday, January 25, 2023

Source URL: <https://techtransfer.cancer.gov/availabletechnologies/e-033-2013>